CONNECTS Seminar


Leveraging Partnerships with the FDA : Advice for Startups

Courtney Williamson, PhD, CEO, AbiliLife

Elora Gupta, PhD, Project Olympus Advisor

Swartz Center for Entrepreneurship Carnegie Mellon University

April 2, 2019¹



Agenda

AbiliLife's Story


Engaging with the FDA

AbiliLife FDA Engagement and Product Roadmap

Conclusions



The Journey



The Product

Intended Use/Indication for Use:

Back brace designed specifically for geriatric and neuromuscular patients (i.e. Parkinson's disease, spinal stenosis, osteoporosis, etc.).

Rolls shoulders up and back for more natural and healthy posture.

Rigid back panel supports from tailbone to the top of the shoulder blades.

Classification: I, Exempt Regulation: 21 CFR 890.3490 Description: Truncal Orthosis Code: IQE





Post-Marketing : 2016 - Today

Then:



Originally designed for PD patients







600 Pre-existing codes didn't include PD









Only CMS reimbursed for the Calibrace+

Sole-providership helped with payment



Engaging with the FDA



FDA Warning Letter, 2015

40000 de



Design validation to conform to user needs


Design validation under actual/simulated use conditions

Design input requirements

- Design risk analysis
- Document review and approval

.... not an exhaustive listing of objectionable conditions !

FDA Warning Letter, 2015



Devices listing

- Receiving, reviewing, evaluating complaints
- Failure to meet product specifications
- Corrective and Preventive Actions (CAPAs)
- Software, data processing systems validation
- Evaluation of potential suppliers
- Records of acceptable suppliers
- Device history records not established
- Quality audits

.... not an exhaustive listing of objectionable conditions !another warning letter in 2016!

June 15, 2018: Theranos Founder and Former Chief Operating Officer Charged in Alleged Wire Fraud Schemes



Schemes to Defraud Investors, Doctors, and Patients



FDA		S FC	חחו		A to Z Index Follow FDA En Español					
	DA U.S. FOOD & DRUG					Search FDA			٩	
=	Home	Food	Drugs	Medical Devices	Radiation-Emitting Products	Vaccines, Blood & Biologics	Animal & Veterinary	Cosmetics	Tobacco Products	

FDA Regulates: \$1 trillion worth of products a year


FDA Mission: Protect & Promote US Health

FDA Modernization: Streamline, Expedite, Incentivize, Least Burdensome Approach*


Leverage by early engagement and partnership with FDA

*: Minimum amount of necessary information, most efficient manner, right time

What is a Medical Product?



General Fitness / Wellness Trackers (count steps, sleep comfort....) SaaS for consumer use/convenience/entertainment (hail ride, order food,)




New Research

dute

MEDICAL PRODUCT STARTUP IS PARTICULARLY TOUGH





I. Labeling

Primary source of legal information for patient, caregivers, physicians, payers Intended Use* (overall purpose of device)

Indications for Use* (population, condition, endpointssubstantiated by VALID SCIENTIFIC EVIDENCE)

Contraindications, Warnings, Precautions

Instructions for Use: Physician, Patient

Device Description

Specifications

Safety

Effectiveness

* START	
REVIEW REVISE UPDATE	

discs are linked together by a	user (Figure 1) is a self-expandable, double-disc device made from a Nitinol wire mesh. The 5 short connecting waist. In order to increase its closing ability, the discs contain thin polyeste ecurely serve to each disc by a polyester thread.
	rker bands on the distal and proximal ends of the device. The device contains an end screw o livery and deployment. The device is sterilized with ethylene oxide.
Figure 1. AMPLATZER** PFC	Occluder
	A Topy and due A Left and due C Wate
Indications and Usage	
	uder is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to
reduce the risk of recurrent isch	hemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had sumed paradoxical embolism, as determined by a neurologist and cardiologist following an
reduce the risk of recurrent isc cryptogenic stroke due to a pre evaluation to exclude known ca Contraindications	hemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had sumed paradoxical embolism, as determined by a neurologist and cardiologist following an uses of ischemic stroke.
reduce the risk of recurrent iscl cryptogenic stroke due to a pre- evaluation to exclude known ca Contraindications • Patients with intra-cardiac venous thrombus in the ve	herric stroke in patients, predominantly between the ages of 18 and 60 years, who have had usuand paradoxical emotivations and extended and and and and and and and and and an
reduce the risk of recurrent lisc cryptogenic stroke due to a pre evaluation to exclude known ca Contraindications Patients with intra-cardiac venous thrombus in the ve Patients whose vasculatur sheath size.	hemic school in platefing, pedominantly between the egges of 15 and 60 years, who have had uses of siddemice streke. mask, vegatalon, land or thromboa at the intended site of implant, or documented evidence sites through which access to the PFO is gained, is inadequate to accommodate the appropriate e. through which access to the PFO is gained, is inadequate to accommodate the appropriate
reduce the risk of recurrent liad cryptogenic stroke due to a pre evaluation to exclude known ca Contraindications - Patients with intra-cardisic: venous thrombus in the ve - Patients whose vasculatur sheath size. - Patients with anatomy in w infravascular structures, sc	here: picke in pulsels, prodominantly believe the sign of 18 and 59 years, who here had using analyzed and believes the second state of the second state of observations uses of abundless of the second state of the second state of observations sets the second state. The second state of the second state of second states of the second states of the second states in the second state of second states and second states and states and states and states and states and second states and states and states and states and second states and states and states and states and second states and states and states and states and states and states and states and states and states and states and states and states and s
reduce the risk of recurrent list cryptogenic stroke due to a pre- evaluation to exclude known co. Contraindications Patients with intra-cardiac: venous thrombus in the ver- Patients with anatomy in w intravascular structures, so Patients with other sources Patients with other sources	There is being an particle, processing the bears the gaps of 18 and 59 years, who have halfs and parallelization of the second
reduce the risk of recurrent list cryptogenic stroke due to a pre- evaluation to exclude known co. Contraindications Patients with intra-cardiac: venous thrombus in the ver- Patients with anatomy in w intravascular structures, so Patients with other sources Patients with other sources	here: picke in pulsels, prodominantly believe the sign of 18 and 59 years, who here had using analyzed and believes the second state of the second state of observations uses of abundless of the second state of the second state of observations sets the second state. The second state of the second state of second states of the second states of the second states in the second state of second states and second states and states and states and states and states and second states and states and states and states and second states and states and states and states and second states and states and states and states and states and states and states and states and states and states and states and states and s
reduce the risk of recurrent list cryptogenic stroke due to a pre- evaluation to exclude known co. Contraindications Patients with intra-cardiac: venous thrombus in the ver- Patients with anatomy in w intravascular structures, so Patients with other sources Patients with other sources	hence solve no palledis, prodominantly believes the gain of 11 and 50 years, who have hilds and parallelization of the solution of the solution of the solution of the disclosure at a manual and the solution of the solution of the solution of the disclosure of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of and the AMPL ATZEN *** (C) as galand, is make used in the solution of the solution of which has AMPL ATZEN **** (C) as galand, is make used in the solution of and the AMPL ATZEN ***** (C) as a solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of and the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of and the solution of the solut
reduce the risk of recurrent list cryptogenic stroke due to a pre- evaluation to exclude known co. Contraindications Patients with intra-cardiac: venous thrombus in the ver- Patients with anatomy in w intravascular structures, so Patients with other sources Patients with other sources	hence solve no palledis, prodominantly believes the gain of 11 and 50 years, who have hilds and parallelization of the solution of the solution of the solution of the disclosure at a manual and the solution of the solution of the solution of the disclosure of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of and the AMPL ATZEN *** (C) as galand, is make used in the solution of the solution of which has AMPL ATZEN **** (C) as galand, is make used in the solution of and the AMPL ATZEN ***** (C) as a solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of and the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of and the solution of the solut
reduce the risk of recurrent list cryptogenic stroke due to a pre- evaluation to exclude known co. Contraindications Patients with intra-cardiac: venous thrombus in the ver- Patients with anatomy in w intravascular structures, so Patients with other sources Patients with other sources	hence solve no palledis, prodominantly believes the gain of 11 and 50 years, who have hilds and parallelization of the solution of the solution of the solution of the disclosure at a manual and the solution of the solution of the solution of the disclosure of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of the solution of and the AMPL ATZEN *** (C) as galand, is make used in the solution of the solution of which has AMPL ATZEN **** (C) as galand, is make used in the solution of and the AMPL ATZEN ***** (C) as a solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of and the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of the solution of the solution of the solution of and the solution of the solution of and the solution of the solut

II. Regulatory Pathway

Determined by proposed labeling, associated risk, legal existence of 'predicate' Medical Product & Accessory

Registration, Listing

Class I (Exempt) 510(k) Class II (Predicate)

De Novo Class I/II (No predicate)

PMA Class III

Humanitarian Device Exemption (rare disease) Tool for Medical Product dev. *

Medical Device Development Tool (MDDT)

Case for Quality

Accreditation Scheme for Conformity Assessment (ASCA)


Software Pre-Certification (Pre-Cert)

*: Recent initiatives, pilot programs

Labeling - Risk - Regulatory Pathway


Low Risk	Moderate Risk	High Risk							
Class I: ~ 47% Pathways - ~ 95% Exempt - Few De Novo	Class II: ~ 43% Pathways - 510(k) - 510(k) exempt - De Novo	Class III: ~ 10% Pathway - PMA							
Impact of Proposed Label									
Surgical Apparel- Exempt	Hearing Aids: Air Conduction-510(k) exempt Bone Conduction-510(k)	Pacemaker Artificial lung							
Wrap for Restless Leg Syndrome- <i>De Novo</i>	Self-Fitting - <i>De Novo</i> App for addiction therapy- <i>De Novo</i>								

De Novo Pathway



DATA SOURCE: FDA

Trending for CMU Startups Trailblazing..novel device showcasing advanced technology Unique, patient focused labeling First to Market Strategies to delay competition



FDA Quote : "Most, if not all advertising, is labeling"



17 Pins • 368 Followers





REAL CHANGE










Medical Device AD

FDA conducted a query of the MDR database for all reports entered between January 1, 2008 and October 31, 2018 referring to a saline- or silicone-filled breast implant with the following search terms taken from the website *Healing Breast Implant Illness*

> GERD Cough Sick Raynaud Numbness Hormone Candida Intoleran Allergies Choking Dry skin Muscle pain Autoimmune Joint Yeast Heart pain Slow healing Dehydration Vertigo Menopause Shortness breath Fibromyalgia Cold Depression Rheumatoid arthritis Panic attack Dry hair Liver Gallbladder Gastrointestinal issues Easy bruising Allergy EBV Toxic shock Memory loss Pancreatitis Weight Urinary tract Brain Fog Premature aging Dying Libido Connective tissue Fatigue Frequent urination Toxic Reflux Transported to the second secon Reflux Throat clearing Joint pain Metallic taste Thyroid Adrenal Slow recovery Doch Chest discomfort Sjogren Leaky gut Multiple sclerosis Rash Chest discomfort Sjogren Inflammation Difficulty swallowing Ear ringing Fever Migraine Night sweats Heart palpitations Parathyroid SIBO Anxiety Hysterectomy Early menopause Gastritis Sinus Illness Scleroderma Lyme disease Hashimoto Tingling Heart rate Acid reflux Insomnia IBS Arthritis Headaches Sleep Kidney Dry eyes Lupus

FDA Quote : "FDA monitors reports of adverse events and other problems with medical devices, alerts health professionals and public ...

IOV



Why Early and Continued FDA engagement?

Align of desired **Labeling** and **Streamlined Development Pathway** - particularly for De Novos

Obtain strategic FDA feedback to **refine Differentiation Options and Decision Making**

Critical for successful Funding - particularly SBIR/STTR, DoD

Important for VCs as well - particularly after Theranos debacle


Adds to Exit Strategy and Valuation

No fees

FDA White Oak Campus in MD

CAUTION





Up-to-date Regulatory Intelligence vital - best positioning of company proposals


Poor briefing document - unanticipated FDA queries, suboptimal feedback

All captured in meeting minutes - permanent in FDA database

Poor performance - FDA's assessment of company merit and capabilities



FDA strategy and engagement NOT a DIY activity - wise to invest in right expertise



AbiliLife FDA Engagement and Product Roadmap

Label Development : Differences in wording impacting Evidentiary Requirements and Submission Strategy

Alert for High Fall Risk \$\$\$

Versus

Reduce Fear of Fall \$\$\$\$

Versus

Prevention of Fall \$\$\$\$\$\$\$\$

Continuous FDA Engagement



FDA Pre-Submission Meeting: Full portfolio

CMS Contact

Comment on draft FDA Guidance

Member, Coalition for Software guidances Pre-Submission Supplement: Software Platform

2017

Followup FDA T/Cs

Battelle/CMS contact on Quality Payment Strategies

FDA MDDT designation Submission **2018**

Pre-Submission Supplement: Portfolio, Life Cycle Optimization, Rare disease development

Parallel FDA-CMS feedback

Private Payer, VA engagement

2017-2018: Calibrace+ Post-Marketing Experience

CORE COMPENTENCIES

Calibrace+ Orthotic Back Brace for Spinal Disorders

- Certified durable medical equipment company (Board of Certification/ Accreditation)
- HCPCS codes L1310; L0650; L0651; L0648; L04574
- **PAST PERFORMANCE**
- Hospital Providers:
 - o VA Denver Healthcare System
 - o VA Philadelphia Healthcare System
 - o VA Pittsburgh Healthcare System
- Insurance Providers
 - o TriNet
 - o Medicare
 - o Blue Cross Blue Shield
 - o Cigna

DIFFERENTIATORS

• Utility Patent - Pending

STTR grant Phase I

Clinical Trial - Pending

National Science Foundation

• Calibrace+

back brace engineered by AbiliLife

- Provides upper torso support
- Decreases fear of falling
- Used for 600+ diagnosis codes
- Made in America 📖

ICD-10 code, L0457; eligible for use for over 600 diagnosis codes

Real-World Evidence

PORTFOLIO OPTIMIZATION

Calibrace+:

- Extension of population: Neuromuscular diseases
- Extension of indication: Lower back pain

Smart Calibrace

- Extension of population and subgroups
- Patient Reported Outcome endpoints meaningful to both FDA and CMS

2018: Patent Allowed Claims

Attorney Docket No. 0085022-000003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Williamson, et al.

Application No.: 14/728,138

Filed: June 02, 2015

Confirmation No. 7702

) PATENT APPLICATION

PHYSIOTHERAPEUTIC, AMBULATORY, AND MOBILITY VEST

Group Art Unit: 3772


Examiner: Lewis, Kim M.

ALLOWED CLAIMS

PORTFOLIO OPTIMIZATION

Additional Device Description Claim:

Only back brace that improves posture and balance by lifting the shoulders up and back and giving entire back support **2018:** AbiliLife Optimized Portfolio based on Post-Marketing Experience - FDA Pre-Submission Supplement Meeting





Impact of FDA Engagement on E.g. Manufacturer, Distributor, Investor, Grant Applications

Value Assessment of Portfolio

External Communications

Portfolio Value Enhancement

Summary of Learnings as an Entrepreneur

- Interact with the FDA early and often
- Make sure that your investors understand the FDA process
- View the FDA as a partner and not as a foe
- Understand the value of having an FDA approved product for when you value your company